Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Peritoneal Cancer: early-phase trial registry
9 of 33 indexed Peritoneal Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #463 of 28,707 conditions by registered trial count.
33 US clinical trials · 9 currently recruiting · #463 of 28,707 conditions by registered trial count
Peritoneal Cancer: 33 US clinical trials tracked, 9 recruiting.
Peritoneal Cancer is the subject of 33 registered US clinical trials on ClinicalTrials.gov, 9 of them currently open to new participants. 4 are in Phase 3-4 (later-stage) and 25 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 3 of these trials.
Enrollment posture brief
Registry condition peritoneal-cancer
OPEN 9 | RECR 27% | LATE 4 | EARLY 25 | RANK #463 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Atherosclerotic Cardiovascular Disease (27% recruiting · 22 trials)
Peritoneal Cancer lists 9 open slots (27% of 33 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Peritoneal Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Peritoneal Cancer is recruiting below its size-band peers.
9 of 33 indexed trials (27.3%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Peritoneal Cancer trials is spread across many organizations.
Memorial Sloan Kettering Cancer Center accounts for 3 of 33 trials (9.1%). 25 distinct sponsors appear on at least one study for this condition label.
-
Most Peritoneal Cancer trials plan to enrol fewer than 100 people.
Median target enrolment is 50 among the 33 trials that report a genuine target (sentinel values excluded). 21 of those (63.6%) plan for fewer than 100 participants.
-
Peritoneal Cancer research is mostly interventional.
32 interventional and 1 observational studies make up this index (97% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
33 total, page 1 of 1
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
AbbVie
NCT05445778
A Study of ZN-c3 in Patients With Ovarian Cancer
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals
NCT04516447
Using Aspirin to Improve Immunological Features of Ovarian Tumors
H. Lee Moffitt Cancer Center and Research Institute
NCT05080946
Study of Acute Normovolemic Hemodilution (ANH) in People With Ovarian Cancer Who Are Having Cytoreductive Surgery
Memorial Sloan Kettering Cancer Center
NCT06290193
An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib
University of Colorado, Denver
NCT05887609
BP1001-A in Patients With Advanced or Recurrent Solid Tumors
Bio-Path Holdings
NCT04196257
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
Alexander B Olawaiye, MD
NCT05071937
Microdevice In Ovarian, Fallopian Tube, And Peritoneal Cancer
Brigham and Women's Hospital
NCT04701645
Intra-tumoral (IT) Injection of vvDD-hIL2-2-RG-1 for Metastatic Gastrointestinal and Peritoneal Tumors
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
NCT07001592
Tempus Priority Study: A Pan-tumor Observational Study
Tempus AI
NCT05179824
Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery
CanariaBio
NCT04498117
Depression Treatment and Screening in Ovarian Cancer Patients
M.D. Anderson Cancer Center
NCT00515372
Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors
SystImmune
NCT06714617
A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib
Dana-Farber Cancer Institute
NCT02873962
A Study of the Drug I131-Omburtamab in People With Desmoplastic Small Round Cell Tumors and Other Solid Tumors in the Peritoneum
Memorial Sloan Kettering Cancer Center
NCT04022213
Genetic Testing in African Americans
Augusta University
NCT05591131
Nudge to Gynecologic Oncology
Abramson Cancer Center at Penn Medicine
NCT06451263
A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.
CanariaBio
NCT05335993
A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)
pharmaand
NCT01891344
A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression
AbbVie
NCT04209855
A Randomized Study of Safety and Efficacy of Pazopanib and Gemcitabine in Persistent or Relapsed Ovarian Cancer
Linda R Duska
NCT01610206
Standard Infusion Carboplatin Versus Prophylactic Extended Infusion Carboplatin in Patients With Patients With Recurrent, Ovary, Fallopian Tube, and Primary Peritoneal Cancer
Memorial Sloan Kettering Cancer Center
NCT01248962
A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
ImmunoGen
NCT04296890
Study of Oral ENMD-2076 Administered to Patients With Ovarian Cancer
CASI pharmaceuticals
NCT01104675
Ph II Study of Wkly Topotecan + Bevacizumab in Plat. Resistant/Recurrent Gyn Cancers
Benaroya Research Institute
NCT00343044
A Study of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic Cancers
AA Secord
NCT02728830
Phase 1b Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer
ImmunoVaccine Technologies, Inc. (IMV Inc.)
NCT03332576
A Phase I Clinical Trial of Autologous Dendritic Cell Vaccine for Recurrent Ovarian or Primary Peritoneal Cancer
Abramson Cancer Center at Penn Medicine
NCT00683241
Docetaxel and PTK787 in Metastatic Breast Cancer Patients and Gynecological Cancer Patients
Dana-Farber Cancer Institute
NCT00268918
Evaluation of GTPase Inhibition by Post-operative Intravenous Ketorolac in Ovarian Cancer Patients
New Mexico Cancer Research Alliance
NCT02470299
PH I SRC Kinase, Dasatinib Combo Paclitaxel & Carboplatin in Pts w Ovarian, Peritoneal, & Tubal Cancer
AA Secord
NCT00672295
Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors
Nagla Abdel Karim
NCT03023319
Oxaliplatin and Paclitaxel Plus Bevacizumab in Advanced Peritoneal Carcinomatosis
M.D. Anderson Cancer Center
NCT00491855
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 14 |
| Phase 2 | 11 |
| Phase 3 | 4 |
Top Sponsors
Named interventions
Most-linked intervention names on Peritoneal Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Peritoneal Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Peritoneal Cancer page
33 registered trials, 9 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 9 Peritoneal Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Memorial Sloan Kettering Cancer Center sponsors the most Peritoneal Cancer trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Peritoneal Cancer condition card totals 33 registered trials; most-linked intervention Paclitaxel; top US site state Massachusetts. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.